Regeneron Pharmaceuticals, Inc. REGN NDXSPX

Healthcare · Biotechnology · United States

https://www.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Market & Price

Market Cap

$64.45B

Current Price

$614.78

High / Low (52W)

$810.08 / $480.44

Beta

0.30

Valuation

Stock P/E

15.02

Industry PE

23.65

Forward P/E

11.43

PEG Ratio

1.07

Book Value

$308.32

Price to Book

1.99

P/S

4.32

EV/EBITDA

12.89

Dividend Yield

0.61%

Profitability & Returns

ROCE

14.57%

ROE

14.55%

ROA

6.13%

Profit Margin

29.65%

Op Margin

20.66%

EPS (Latest Qtr)

$6.75

EPS (TTM)

$40.94

Balance Sheet & Liquidity

Debt/Equity

0.09

Quick Ratio

2.84

Current Ratio

3.56

Debt

$2.71B

Total Assets

$40.56B

Current Assets

$18.02B

Working Capital

$13.65B

Ownership

Promoter Holding

2.03%

Chg in Prom Hold

FII / Inst Holding

92.12%

Chg in FII Hold

-0.02%

Financial Snapshot

Enterprise Value

$56.50B

Total Revenue (TTM)

$14.92B

EBITDA

$4.38B

Free Cash Flow

$3.27B

Operating Cash Flow

$5.01B

Shares Outstanding

103.02M

Gross Margin

43.89%

Payout Ratio

8.74%

Growth (CAGR)

Revenue 5Y

5.62%

Profit 5Y

1.26%

Revenue (YoY)

19.00%

Earnings (YoY)

-7.20%

PROS

Excellent profit margin of 29.6%.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	REGN Regeneron Pharmaceuticals, Inc. NDXSPX	614.78	15.02	$64.45B	0.61%	14.57%	14.55%	5.62%	1.26%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	1.32B	1.47B	1.50B	1.58B	1.51B	1.61B	1.66B	1.93B	1.37B	1.58B	1.74B	1.86B	1.83B	1.95B	2.29B	2.42B	2.53B	5.14B	3.45B	2.97B	2.86B	2.94B	3.16B	3.16B	3.36B	3.15B	3.55B	-	-	3.03B	3.68B	3.75B	3.88B	3.61B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	464.30M	530.20M	521.60M	584.60M	669.40M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.56B	3.15B	3.23B	3.30B	2.94B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.97B	2.07B	2.12B	2.40B	2.19B
Operating Income	392.42M	-	329.31M	291.63M	362.80M	-	430.54M	550.31M	559.93M	-	567.20M	622.20M	626.90M	-	480.00M	315.60M	738.50M	-	700.10M	656.40M	1.05B	-	1.11B	3.35B	1.85B	1.26B	1.11B	1.22B	946.70M	1.02B	1.11B	751.40M	1.07B	-	-	591.70M	1.08B	1.11B	898.60M	744.80M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.04B	1.66B	1.92B	1.20B	967.30M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.70M	3.60M	19.30M	12.20M	12.90M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	905.00M	1.52B	1.76B	1.04B	831.20M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	96.30M	127.10M	303.30M	199.10M	104.00M
Net Income	210.40M	154.99M	181.38M	196.22M	264.80M	253.12M	248.90M	387.70M	388.30M	173.50M	478.00M	551.40M	594.70M	820.40M	461.10M	193.10M	669.60M	792.00M	624.60M	897.30M	842.10M	1.15B	1.12B	3.10B	1.63B	973.50M	852.10M	1.32B	817.80M	968.40M	1.01B	722.00M	1.43B	-	-	808.70M	1.39B	1.46B	844.60M	727.20M
Diluted EPS	1.82	1.34	1.59	1.69	2.27	2.19	2.16	3.34	3.32	1.50	4.16	4.82	5.17	7.15	3.99	1.68	5.86	6.93	5.43	7.61	7.39	10.24	10.09	27.97	14.33	8.61	7.47	11.66	7.17	8.50	8.89	6.27	12.41	-	-	7.27	12.81	13.62	7.86	6.75
R&D Expense	425.92M	-	470.11M	559.93M	543.05M	-	507.44M	509.98M	529.75M	-	498.60M	529.30M	557.00M	-	486.10M	885.50M	526.00M	-	583.90M	722.00M	684.60M	-	742.90M	714.20M	665.40M	843.80M	794.30M	911.30M	1.10B	1.09B	1.08B	1.25B	1.20B	1.27B	-	1.33B	1.42B	1.48B	-	1.54B

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	4.86B	5.87B	5.15B	6.56B	8.50B	-	12.17B	13.12B	14.20B	14.34B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.56B	1.82B	1.97B	2.10B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.61B	11.30B	12.23B	12.24B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.87B	7.25B	8.24B	8.54B
Operating Income	-86.25M	-74.10M	-97.47M	-205.16M	457.71M	743.05M	823.92M	1.25B	1.33B	2.08B	2.53B	2.21B	3.58B	-	4.74B	4.05B	3.99B	3.70B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.26B	4.69B	5.32B	5.82B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	59.40M	73.00M	55.20M	43.80M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.86B	4.20B	4.78B	5.23B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	520.40M	245.70M	367.30M	725.80M
Net Income	-79.13M	-67.83M	-104.47M	-221.76M	750.27M	413.74M	338.13M	636.06M	895.50M	1.20B	2.44B	2.12B	3.51B	-	4.34B	3.95B	4.41B	4.50B
Diluted EPS	-	-	-1.26	-2.45	6.75	3.72	2.98	5.52	7.70	10.34	21.29	18.46	30.52	-	38.22	34.77	38.34	41.48
R&D Expense	274.90M	398.76M	489.25M	529.51M	625.55M	859.95M	1.27B	1.62B	2.05B	2.08B	1.47B	2.45B	2.65B	2.86B	3.59B	4.44B	5.13B	5.85B

Compounded Sales Growth

5 Years:	5.62%
1 Year:	19.00%

Compounded Profit Growth

5 Years:	1.26%
1 Year:	-7.20%

Stock Price Performance

1 Year:	+26.08%
6 Months:	-21.70%
3 Months:	-21.23%
1 Month:	-10.30%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	741.20M	1.09B	1.32B	2.08B	2.95B	3.84B	5.61B	6.97B	8.76B	11.73B	14.81B	17.16B	-	29.21B	33.08B	37.76B	40.56B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.88B	19.48B	18.66B	18.02B
Cash & Equivalents	498.93M	247.80M	207.07M	112.57M	483.61M	230.28M	535.61M	648.72M	809.10M	535.20M	812.70M	1.47B	1.62B	2.19B	-	3.11B	2.73B	2.49B	3.12B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.40B	2.58B	3.09B	3.20B
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.33B	5.67B	6.21B	5.74B
Total Liabilities	-	-	344.44M	561.62M	837.85M	835.11M	998.94M	1.29B	1.95B	2.52B	2.62B	2.98B	3.72B	6.14B	-	6.55B	7.11B	8.41B	9.30B
Current Liabilities	-	-	93.58M	109.06M	148.27M	163.55M	298.83M	654.66M	811.16M	1.24B	1.14B	1.44B	2.10B	2.70B	-	3.14B	3.42B	3.94B	4.37B
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	0	1.98B	-	1.98B	1.98B	1.98B	1.99B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.70B	2.70B	2.70B	2.71B
Total Equity	459.35M	421.51M	396.76M	527.82M	485.73M	1.26B	1.96B	2.55B	3.65B	4.45B	6.14B	8.76B	11.09B	11.03B	-	22.66B	25.97B	29.35B	31.26B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	132.20M	134.92M	137.82M	139.42M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-89.09M	-69.94M	99.22M	-141.68M	-74.61M	588.60M	752.43M	1.33B	1.49B	1.31B	2.20B	2.43B	2.62B	-	5.01B	4.59B	4.42B	4.98B
Investing Cash Flow	30.82M	-2.15M	-437.03M	128.47M	-81.07M	-355.45M	-420.78M	-907.60M	-1.05B	-1.01B	-1.46B	-2.03B	-70.60M	-	-3.78B	-3.19B	-2.47B	-629.10M
Financing Cash Flow	-192.86M	31.36M	243.31M	384.25M	-97.65M	72.19M	-218.55M	-262.80M	-700.50M	-24.40M	-77.10M	-252.10M	-1.97B	-	-1.01B	-1.79B	-2.20B	-3.72B
Capital Expenditure	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1.62B	-926.40M	-881.60M	-1.21B
Free Cash Flow	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.40B	3.67B	3.54B	3.77B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	221.30M	-381.20M	-248.10M	634.40M
Share Buybacks	-	-	-	-	-	-	-	-	0	0	4.40M	275.90M	5.85B	1.65B	2.08B	2.23B	2.60B	3.44B
Dividends Paid	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	370.30M

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	87.2%	86.2%	86.1%	85.4%
Operating Margin %	-	-	-	-	-	-	-	-	27.4%	35.4%	49.3%	33.7%	42.1%	-	38.9%	30.9%	28.1%	25.8%
Net Margin %	-	-	-	-	-	-	-	-	18.4%	20.4%	47.5%	32.3%	41.3%	-	35.6%	30.1%	31.1%	31.4%
ROE %	-18.8%	-17.1%	-19.8%	-45.7%	59.7%	21.1%	13.3%	17.4%	20.1%	19.5%	27.9%	19.1%	31.9%	-	19.1%	15.2%	15.0%	14.4%
ROCE %	-	-11.4%	-9.9%	-17.5%	23.9%	28.0%	25.9%	26.1%	23.2%	27.3%	24.6%	17.4%	24.7%	-	18.2%	13.6%	11.8%	10.2%

Shareholding Pattern

Insiders

2.03%

Institutions

92.12%

Public Float

94.03%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.69%	8.95M	$5.50B
2	Vanguard Capital Management LLC	6.46%	6.65M	$4.09B
3	State Street Corporation	4.53%	4.66M	$2.87B
4	Dodge & Cox Inc.	4.33%	4.46M	$2.74B
5	JPMORGAN CHASE & CO	4.19%	4.31M	$2.65B
6	Franklin Resources, Inc.	2.64%	2.72M	$1.67B
7	Geode Capital Management, LLC	2.53%	2.61M	$1.60B
8	Price (T.Rowe) Associates Inc	2.11%	2.18M	$1.34B
9	Nuveen, LLC	2.00%	2.07M	$1.27B
10	LOOMIS SAYLES & CO L P	1.86%	1.91M	$1.18B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for REGN

No recent headlines available.

REGN · Healthcare